MELITAC 12.1

Developed for: melanoma
Investigated by: Craig L Slingluff, Jr · National Cancer Institute (NCI) · Oncovir, Inc. · University of Virginia

today NCT01585350 · Ph 1 NCT00977145 · Ph 1

201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT01585350	Oct 2012 → Jul 2014	melanoma	Craig L Slingluff, Jr	Completed	No outcome recorded
Phase 1	NCT00977145	Nov 2009 → Oct 2012	melanoma	Craig L Slingluff, Jr	Terminated	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT01264731 Comparator	Jan 2011 → Jun 2012	melanoma	University of Virginia	Completed	No outcome recorded

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	MELITAC 12.1	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00977145 ↗ 2 NCT01264731 ↗ NCT01585350 ↗
Modality	Vaccine	“systemic vaccination with MELITAC 12.1” NCT00977145 ↗
Route	Other	“The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.” NCT00977145 ↗
Route	Subcutaneous	“The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.” NCT00977145 ↗